Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupHKSE:00575 14 PS Ratio is 86.36 as of Aug. 12, 2026, which is 141% above its 10-year median of 35.85. GuruFocus rates HKSE:00575 with a GF Score™ of 14/100 and a GF Value™ of HK$0.57 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Regent Pacific Group ranks worse than 97.58% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Regent Pacific Group's share price is HK$0.95.
Regent Pacific Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.01. Hence, Regent Pacific Group's PS Ratio for today is 86.36.
The historical rank and industry rank for Regent Pacific Group's PS Ratio or its related term are showing as below:
HKSE:00575'
s PS Ratio Range Over the Past 10 Years
Min: 4.49 Med: 35.85 Max: 900
Current: 86.38
During the past 13 years, Regent Pacific Group's highest PS Ratio was 900.00. The lowest was 4.49. And the median was 35.85.
HKSE:00575's PS Ratio is ranked worse than 97.58% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.355
vs HKSE:00575: 86.38
Regent Pacific Group Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Regent Pacific Group was -54.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -39.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -21.90% per year.
During the past 13 years, Regent Pacific Group's highest 3-Year average Revenue per Share Growth Rate was 98.40% per year. The lowest was -77.30% per year. And the median was -18.60% per year.
Regent Pacific Group (HKSE:00575) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Regent Pacific Group PS Ratio Related Terms
Regent Pacific Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Regent Pacific Group's Share Price of today is HK$0.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Regent Pacific Group (HKSE:00575) has a PS Ratio of 86.36 as of Aug. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Regent Pacific Group and its competitors. This is 141% above median its historical median of 35.85. Over the past decade, Regent Pacific Group's PS Ratio has ranged from 4.49 to 900.00. According to the industry distribution chart, Regent Pacific Group ranks #929 out of 952 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is Regent Pacific Group's PS Ratio too high?
Regent Pacific Group's current PS Ratio of 86.36 is 141% above median its 10-year median of 35.85. Over the past 10 years, this metric has ranged from a low of 4.49 to a high of 900.00. The Drug Manufacturers industry median PS Ratio is 2.36. Regent Pacific Group's value of 86.36 is 3567.1% above this industry median. Based on the distribution chart, Regent Pacific Group ranks #929 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #929 out of 952 companies for PS Ratio. This places Regent Pacific Group in the lower half of its industry. The industry median PS Ratio is 2.36. Regent Pacific Group's value of 86.36 is 3567.1% above this benchmark. Historically, Regent Pacific Group's own PS Ratio has ranged from 4.49 to 900.00 over the past decade. While the company's 10-year median is 35.85 vs. the industry median of 2.36, Regent Pacific Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.36, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regent Pacific Group's current PS Ratio of 86.36 is 3567.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current PS Ratio is 86.36, which is 141% above median its own 10-year median of 35.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Based on GuruFocus' analysis, Regent Pacific Group (HKSE:00575) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.57, compared to a current price of HK$0.95 — trading 66.7% above its estimated fair value. The current PS Ratio is 86.36, which is 141% above median its 10-year median of 35.85 and 3567.1% above the Drug Manufacturers industry median of 2.36. Regent Pacific Group's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Regent Pacific Group (HKSE:00575), the current PS Ratio is 86.36 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regent Pacific Group (HKSE:00575) Overvalued in 2026?
Based on GuruFocus' analysis, Regent Pacific Group stock appears to be overvalued.
The current stock price of HK$0.95 is trading 66.7% above its estimated GF Value™ of HK$0.57.
GuruFocus considers Regent Pacific Group to be Significantly Overvalued.
Key valuation signals for HKSE:00575:
PS Ratio: 86.36 (141% above median its 10-year median of 35.85)
GF Value™: HK$0.57 vs. price of HK$0.95 (66.7% above fair value)
Industry Position: 3567.1% above the Drug Manufacturers median (#929 of 952)
No single metric tells the full story. See the HKSE:00575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
14GF Score
Get the complete analysis for HKSE:00575
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00575 has been successfully added to your 
